Understanding T Cell Changes in Renal Medullary Carcinoma to Find New Treatments
Elucidating T Cell Ferroptosis in Renal Medullary Carcinoma: 3D Genome Architecture Rewiring and Therapeutic Alleviation
This project explores how immune cells called T cells change in patients with a rare kidney cancer, aiming to find better ways to fight the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11136309 on NIH RePORTER |
What this research studies
Renal medullary carcinoma (RMC) is a very aggressive kidney cancer that mainly affects young people of African descent, especially those with sickle cell disease. Current treatments are limited, and while immune therapies show promise, we need to better understand how the immune system interacts with RMC. This project looks closely at the 3D structure of genetic material within T cells from RMC patients to see how these cells are affected by the cancer. By understanding these changes, we hope to uncover new targets for therapies that could make immune treatments more effective for RMC.
Who could benefit from this research
Good fit: This research is particularly relevant for young individuals of African descent diagnosed with renal medullary carcinoma, especially those with sickle cell disease.
Not a fit: Patients without renal medullary carcinoma or those not of African descent may not directly benefit from this specific research focus.
Why it matters
Potential benefit: If successful, this work could lead to new treatment strategies or improve existing immune therapies for patients with renal medullary carcinoma.
How similar studies have performed: While immune checkpoint blockades have shown some promise in RMC, the specific approach of examining 3D chromatin architecture in T cells in this context is relatively novel.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Yang, Liuqing — University of Tx Md Anderson Can Ctr
- Study coordinator: Yang, Liuqing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.